Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$60M, compared with -$52.78M a year earlier.
Context
- Retained earnings amounted to 552.2% of total assets at the end of Q1 FY2026, down 2933.2 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -13.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (58.08M) USD
- Year-over-year change
- -11.5%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (58.08M) | -11.5% |
| FY2024 | 2024-12-31 | (52.07M) | -7.4% |
| FY2023 | 2023-12-31 | (48.48M) | -11.7% |
| FY2022 | 2022-12-31 | (43.39M) | -17.0% |
| FY2021 | 2021-12-31 | (37.08M) | — |
Retained Earnings vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 retained earnings of -$60M is the highest of the 2 companies compared; the peer median is -$141.69M.
- Its year-over-year change of -13.7% is the highest of 2, against a peer median of -26.2%.
- Retained earnings amounts to 552.2% of total assets for LIXT, versus a peer median of 459.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$60M | -13.7% | — | 552.2% | |
| Mar 2026 | -$141.69M | -26.2% | — | 459.1% | |
| Peer median (excluding LIXT) | -$141.69M | -26.2% | — | 459.1% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.